BioPharma Dive1 lá
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...
Bristol Adds to Cost Cutting With Outlook Missing Estimates
Bristol Myers Squibb Co. released sales and profit forecasts for 2025 below Wall Street’s expectations — a sign the company’s ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb beat Q4 estimates with $12.34 billion revenue and $1.67 EPS. 2025 guidance lags expectations amid ...
Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
The company also issued a 2025 guidance that fell short of expectations, as some of the company's older drugs face ...
Bristol Myers Squibb's 4Q Beats Forecasts; Generics Dent 2025 Outlook
The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...
Medscape4 lá
Apixaban: A Novel Oral Inhibitor of Factor Xa
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.